BHIC (BioScience Health Innovations) Cash Conversion Cycle: 235.07 (As of Mar. 2026)


BHIC BioScience Health Innovations Inc BHIC
45 GF Score
Price $4.25
GF Value $164.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is BioScience Health Innovations Cash Conversion Cycle?

BioScience Health Innovations BHIC +4.54% 45 Cash Conversion Cycle is 235.07 as of Mar. 2026. GuruFocus rates BHIC with a GF Score™ of 45/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BioScience Health Innovations's Days Sales Outstanding for the three months ended in Mar. 2026 was 28.98.
BioScience Health Innovations's Days Inventory for the three months ended in Mar. 2026 was 208.33.
BioScience Health Innovations's Days Payable for the three months ended in Mar. 2026 was 2.24.
Therefore, BioScience Health Innovations's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2026 was 235.07.


BioScience Health Innovations  (OTCPK:BHIC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BioScience Health Innovations Cash Conversion Cycle Related Terms


BioScience Health Innovations Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for BioScience Health Innovations's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioScience Health Innovations Cash Conversion Cycle Chart

BioScience Health Innovations Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial 0.00 0.00 127.63 40.69 44.34

BioScience Health Innovations Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.64 41.40 121.54 62.53 235.07

BHIC vs SHFH, PETS, SCNX: Cash Conversion Cycle Comparison

For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioScience Health Innovations Cash Conversion Cycle vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BioScience Health Innovations's Cash Conversion Cycle falls into.


BHIC
45GF Score
BioScience Health Innovations Inc BHIC
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioScience Health Innovations Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BioScience Health Innovations's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=16.01+29.37-1.04
=44.34

BioScience Health Innovations's Cash Conversion Cycle for the quarter that ended in Mar. 2026 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=28.98+208.33-2.24
=235.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 235.07 mean?
BioScience Health Innovations (BHIC) has a Cash Conversion Cycle of 235.07 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BioScience Health Innovations and its competitors.
Is BioScience Health Innovations' Cash Conversion Cycle too high?
BioScience Health Innovations' current Cash Conversion Cycle is 235.07. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.10. BioScience Health Innovations' value of 235.07 is 1198.7% above this industry median. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Cash Conversion Cycle compare to SHFH and PETS?
BioScience Health Innovations' Cash Conversion Cycle of 235.07 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.10. BioScience Health Innovations' value of 235.07 is 1198.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Cash Conversion Cycle of 235.07 is 1198.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Cash Conversion Cycle is 235.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.25 — trading 97.4% below its estimated fair value. The current Cash Conversion Cycle is 235.07 and 1198.7% above the Healthcare Providers & Services industry median of 18.10. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Cash Conversion Cycle is 235.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioScience Health Innovations (BHIC) Overvalued in 2026?

Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued. The current stock price of $4.25 is trading 97.4% below its estimated GF Value™ of $164.84. GuruFocus considers BioScience Health Innovations to be Possible Value Trap.

Key valuation signals for BHIC:

  • Cash Conversion Cycle: 235.07
  • GF Value™: $164.84 vs. price of $4.25 (97.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs
  • Industry Position: 1198.7% above the Healthcare Providers & Services median

No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioScience Health Innovations Business Description

Address 14857 South Concord Park Drive, Bluffdale, UT, USA, 84065
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score

Get the complete analysis for BHIC

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.25
Price
$164.84
GF Value